Frontage Holdings IPO: Risk-Reward Is Favourable at the Low-End of Price Range
Frontage Holdings (1521 HK)Â has launched its Hong Kong IPO at a price range of HK$2.55-3.20 per share to raise HK$1.27-1.60 billion ($160-200...
864 Views
Viva Biotech IPO:Â Just About Supporting the Low-End IPO Price Range
Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...
791 Views
India Generic Drugs: Antitrust Suit Could Cost Billions
This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...
894 Views
WuXi AppTec IPO Valuation:Â Not Much Money Left on the Table
WuXi AppTec Co. Ltd. (WUXI HK)Â is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
713 Views
WuXi AppTech IPO Update: Figuring Out the Right AH Premium
WuXi AppTec Co. Ltd. (WUXI HK) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
831 Views